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ENANTIOSELECTIVE SYNTHESIS OF (+)

The pharmacological properties of (:)-lofexidine are evi

AND

(—)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]
1,3-DIAZACYCLOPENT-2-ENE

dent upon the interaction of lofexidine either With (x2 adren

CROSS-REFERENCE TO RELATED
APPLICATIONS

macological properties are the result of the individual

ergic receptors or With any other macromolecule. These phar

properties of its tWo enantiomeric forms, (+)-lofexidine (2)
This application claims priority under 35 U.S.C. §119 to
Us. Provisional Application No. 61/195,309, ?led on Oct. 6,
2008, the entire content of Which is hereby incorporated by
reference in its entirety.

and (—)-lofexidine (3). These chemically distinct entities dif
fer in their a?inities toWard (x2-adrenergic receptors. (—)
lofexidine shoWs about a 10-fold higher a?inity than that of

TECHNICAL FIELD

(+)-lofexidine When both are individually pitted against the

knoWn (x2-adrenergic ligand, 3 [H]-clonidine, for competitive

This application provides a method for the enantio selective

synthesis of (+) and (—) lofexidine or 2-[1-(2,6)-dichlorophe
noXy)-ethyl]-1,3 -diaZacyclopent-2 -ene.
BACKGROUND OF THE INVENTION

displacement from the receptor. This difference betWeen (+)
lofexidine and (—)-lofexidine is mirrored in their unequal
20

capacity to loWer mean arterial blood pressure; the effect of

(:)-lofexidine (1), an imidaZoline With (x2-adrenergic ago
nist properties is clinically utiliZed for the purpose of amelio
rating symptoms of disorders that stem from abberations in

the (x2-adrenoreceptor function. For example, (:)-lofexidine

(+)-lofexidine is apparent at doses as loW as 561 ng/kg, While
that of (—)-lofexidine is not seen even at doses as high as 10
25

ug/kg (Wilffer‘t, et al., Arch. Int. de. Pharmcodynamie el de

has been used as an anti-hypertensive and for treating the

The}: 1985, 273, 18-32). (:)-lofexidine is useful in the treat

physical and psychological symptoms of opiate abstinence in
opiate-addicts (Wilkins, et al., Clin. Pharmacol. Ther’. 1981,

30, 752-757; andAkhurst, Pharmacoepidemiology andDrug
Safety 2000, 9, 43-47).

ment of hypertension, as Well as in the treatment of With
30

draWal symptoms in opiate addicts. Accordingly, the enanti

oselective synthesis and usage of solely (—)-lofexidine has

been attempted. Three distinct approaches toWard the synthe
35

sis of (—)-lofexidine are Well knoWn, and are described beloW.

Optical resolution of (:)-lofexidine into (+)-lofexidine and
40

H
N

H
N

I)

I)

N

N

l, Lofexidine

(—)-lofexidine. In the Work of Biedermann et. al., (+) and
(—)-dibenZoyl tartaric acids are reacted With (:)-lofexidine
and subsequently alloWed to crystallize from acetone (Bied
ermann et al., J. Med. Chem. 1986, 29, 1183-1188). After a

45

2, (—)-Lofexidine

total of 4 recrystalliZations, optically pure (+)-lofexidine is
obtained (Where (+)-tartaric acid is employed) and (—)-lofexi
dine is obtained (Where (—)-tartaric acid is employed). HoW
ever, the overall yield of this resolution process is typically

50

5-10%, making this methodology impractical for large scale

preparation.
Enantioselective approach toWard (+)-lofexidine and (—)
55

C1

lofexidine based on amide dehydration, nitrile alcoholysis
and imidaZoline formation: Another approach described in
the Work of Biedermann et. al. employs chirally pure ethyl
lactate as a starting material. The synthesis (Scheme 1)
involves a tWo-step inversion of the ot-chiral center of ethyl

lactate folloWed by amidation, dehydration of the amide,

C1

5.3
3 , (+)-Lofexidine

65

alcoholysis of the resulting nitrile and conversion of the
resulting imino-ether into imidaZoline folloWed by sali?ca
tion by anhydrous HCl. An overall yield of 5% is obtained
after 8 synthetic transformations that employ tWo high
vacuum distillation processes.

US 8,101,779 B2
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Enantioselective approach toward (+)-lofexidine and (—)
Scheme 3. AlCl3—rnediated imidazoline formation in the synthesis of m

lofexidine based on Lewis-acid mediated imidaZoline forma

nitrobiphenylene.

tion: US. Pat. No. 4,518,783 is directed to a synthetic route

toward chirally pure lofexidine (Scheme 2) that begins from

5

A1C13

intermediate 6 of scheme 1.Amidati0n with ethylene diamine

—>

913

is followed by Lewis-acid mediated cycliZation to imidaZo

N02

HZNCHZCHZNHZ

:

line. An overall yield of 4% is obtained over 5 synthetic

OCH3

o/wf

transformations that involve a silica-gel column chromatog

PhCH3, re?ux

72% 66

O
20

raphy process following the Lewis-acid mediated imidaZo
line formation.

QH3
Scheme 2. Lewis-acid mediated imidazoline formation.
C1

No2

C1

20
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Thus, new methods for synthesizing (+) and (—) lofexidine
are needed, which provide greater yields than the processes
known in the art, and which improve the ease and improves

NH;

6
18

the overall ease and yields of the process, without harm to the

stereochemical integrity of the product.

TiC14, THF
30

36%

SUMMARY OF THE INVENTION

chromatography

This invention relates to the chemical transformation of

chirally pure methyl lactate to yield chirally pure (+)-lofexi
35

dine or (—)-lofexidine with better yield than known methods,
and without the usage of additional puri?cation techniques,
such as distillation or chromatography.

One aspect of the present invention provides an enantiose
40

C1

namide to the (+) or (—) imino-ether intermediate by electro
philic attack of the amide oxygen by a trimethoxonium ion

C1
45

0

HCL

lective synthesis of (+) or (—) 2-[1-(2,6-dichlorophenoxy)
ethyl] 1 ,3-diaZacyclopent-2-ene (lofexidine) or a pharmaceu
tically acceptable acid addition salt thereof comprising:
converting (+) or (—) 1 -methyl-1-[2,6-dichlorophenoxy]etha
and, without isolation, converting the (+) or (—) imino-ether
intermediate to (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]

1,3-diaZacyclopent-2-ene by adding ethylene diamine.

o

Optionally, (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3

Cl /\T
?
g

N\>

2

2-propanol
77%

diaZacyclopent-2-ene may be converted into a pharmaceuti

Cl /\r g

NJ

cally acceptable acid addition salt thereof.
Another aspect of the present invention provides an enan

tioselective synthesis of (+) or (—) 2-[1-(2,6-dichlorophe

19

noxy)-ethyl]1,3-diaZacyclopent-2-ene or a pharmaceutically

acceptable acid addition salt thereof comprising: (a) convert
ing (+) or (—) 1-methyl-1-hydroxyethanoate to (+) or (—)

The synthesis of a related imidaZoline; m-nitrobiphe
55

nyline, is also known. (Crassous et al., J. Med. Chem. 2007,
50, 3964-3968). Shown in Scheme 3, a Mitsonubu inversion

[2,6-dichlorophenoxy]ethanoate to (+) or (—) 1-methyl-1-[2,

6-dichlorophenoxy]ethanamide; (c) converting (+) or (—)

of the ot-hydroxy function of methyl lactate yields an analog
of 6. The resulting substituted methyl ester 20 is converted to

1-methyl-1-[2,6-dichlorophenoxy]ethanoate by reacting
with 2, 6-dichlorophenol, triphenylphosphine and diisopropyl
aZodicarboxylate; (b) converting the (+) or (—) 1-methyl-1

60

1-methyl-1-[2,6-dichlorophenoxy]ethanamide to (+) or (—)
imino-ether intermediate by electrophilic attack of the amide
oxygen by a trimethoxonium ion and, without isolation, con

an imidaZoline by heating it with ethylene diamine in dry

verting the (+) or (—) imino-ether intermediate to (+) or (—)

toluene in the presence of AlCl3. This approach fails to yield

by adding ethylene diamine; and (d) optionally converting the

a chirally pure product, as the enantiomeric excess was found

to be 72%.

2-[1-(2,6-dichlorophenoxy)-ethyl]1,3 -diaZacyclopent-2-ene
65

(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo
pent-2-ene into a pharmaceutically acceptable acid addition
salt thereof.

US 8,101,779 B2
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DETAILED DESCRIPTION OF THE INVENTION

meaningful overall yields and does not require additional
puri?cation techniques, such as distillation or column chro

matography.

De?nitions and Abbreviations

While all previous procedures have utiliZed a tWo-step
amide-dehydration and nitrile alcoholysis to generate an

In accordance With this detailed description, the following

imino-ether intermediate, the present method involves a one
step conversion. The present methods utiliZe a direct electro

abbreviations and de?nitions apply. It must be noted that as

used herein, the singular forms “a”, “an”, and “the” include
plural referents unless the context clearly dictates otherWise.
Thus, for example, reference to “an antibody” includes a
plurality of such antibodies and reference to “the dosage”

philic attack of the amide oxygen by a trimethoxonium ion.
This transformation greatly improves the overall ease and
yield of the process, Without harm to the stereochemical

includes reference to one or more dosages and equivalents
thereof knoWn to those skilled in the art, and so forth.

integrity of the con?guration about the ot-carbon.

The publications discussed herein are provided solely for
their disclosure prior to the ?ling date of the present applica

lofexidine With greater yields than schemes knoWn in the art.
In one embodiment, the enantioselective syntheses of the
present invention provide an overall yield of chirally pure
lofexidine or a pharmaceutically acceptable acid addition salt
thereof of at least 50%. In another embodiment, the enanti
oselective syntheses of the present invention provide an over
all yield of chirally pure lofexidine or a pharmaceutically

The present synthesis scheme provides chirally pure

tion. Nothing herein is to be construed as an admission that

the present invention is not entitled to antedate such publica

tion by virtue of prior invention. Further, the dates of publi
cation provided may be different from the actual publication
dates, Which may need to be independently con?rmed.
By the term “subject” or “patient” as used herein is meant

20

acceptable acid addition salt thereof of at least 60%. In a

to include a mammal. The mammal can be a canine, feline,

speci?c embodiment, the overall yield of chirally pure lofexi

primate, bovine, ovine, porcine, camelid, caprine, rodent, or

dine, or a pharmaceutically acceptable acid addition salt
thereof, is at least 64%.
The present invention provides an enantio selective synthe
sis of (+) or (—) lofexidine or a pharmaceutically acceptable
acid addition salt thereof Which comprises converting (+) or

equine. Preferably the mammal is human.
By the term “optionally” is meant that the step or action is
not required or mandatory, but may or may not be performed.
The folloWing abbreviations are used herein:

25

(—) l—methyl-l-[2,6-dichlorophenoxy]ethanamide to the (+)
AlCl3
CDCl3

aluminum chloride
deuterated chloroform

CHZCl2
DIAD

dichloromethane
diisopropyl azodicarboxylate

EtOH

ethanol

HCl
i-PrOH

hydrochloric acid
isopropyl alcohol

30

or (—) imino-ether intermediate by electrophilic attack of the
amide oxygen by a trimethoxonium ion. Then, Without iso
lation, the (+) or (—) imino-ether intermediate is converted to

(+) or (—) lofexidine by adding ethylene diamine. The (+) or
(—) lofexidine can be converted into a pharmaceutically

acceptable acid addition salt if desired. The syntheses of the

K2CO3

potassium carbonate

Na2SO4

sodium sulfate

NMR

nuclear magnetic resonance

Ph3P

triphenylphosphine

35

present invention are described in detail beloW.

Commercially available (+) or (—) methyl lactate (22 or 23)
(for example, obtained from Sigma Aldrich) may serve as

The present invention provides the ?rst instance of an

enantioselective synthesis of lofexidine that proceeds in

starting materials in the present synthesis. The synthesis of
(—)-lofexidine (3), beginning from 22 is illustrated and
described beloW.

Scheme 4. Synthesis of — —lofexidine 3 .

c1

QH
?
'

c1

c1

c1

0

0

C1
ocH3

/\"/

C1

OH

o

Ph3P,
Ether/Hexanes (l :l)

23

0° c. to $411

ocH3

NH3, EtOH

o

D1 AD

NHZ

12 h, 89%
Crystallization

0

from EtOH

24

25

C1

+

_

1- Me3O BF4 CHZClZ, 36 h

I

I

crystallization Cl

2. HZNCHZCHZNH, EtOH, 00 C. to it from hexanes
85%
(one pot)

O

OCH3

NH2+BF4'
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-continued
64% overall yield

C1

C1

100% ee

0

0

Cl

|

HCl

H

conc. aq. HCl

N

i-PrOH-Ether

Cl

H

100%

|

N

N

N
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3

The starting material, commercially available (+) or (—)
methyl lactate ((+) or (—) 1-methyl-1-hydroxyethanoate), is

trimethyloxonium tetra?uoroborate. In one embodiment,
approximately 1.1 equivalents ethylene diamine are added as

reacted With 2,6-dichlorophenol, triphenylphosphine (Ph3P)

an alcohol solution.

and diisopropyl azodicarboxylate (DIAD) to provide (+) or

For example, pure 25 obtained above is dissolved in
reagent-grade CH2Cl2 and treated With an equivalent of tri
methyloxonium tetra?uoroborate. The suspension becomes a

(—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate. In one
embodiment, the reaction takes place in a solvent that dis
solves the (+) or (—) 1-methyl-1-hydroxyethanoate, 2,6

20

cooled to 0° C. and 1.1 equivalents of ethylene diamine are
added as a 10% solution in absolute ethanol. Upon Warming
to room temperature, the turbid mixture is evaporated to

solvent can consist of an approximately 1:1 ratio of a polor

aprotic solvent and a nonpolar solvent. In one embodiment,

dryness and partitioned between CH2Cl2 and 5% aqueous
K2CO3. The organic layer is dried and then evaporated, Which

the polor aprotic solvent is ether, and the nonpolar solvent is
hexanes. In one embodiment, the (+) or (—) 1-methyl-1-hy

provides a solid residue that yields (—)-lofexidine (3) as a
mass of ?ne White needles When crystallized from hexanes.

droxyethanoate is reacted With 2,6-dichlorophenol, triph
enylphosphine and diisopropyl azodicarboxylate at approxi
mately 0° C. and then alloWed to Warm to approximately
room temperature.

30

1,3-diazacyclopent-2-ene (lofexidine) product can be con
verted into a pharmaceutically acceptable acid addition salt
thereof if desired. For example, to provide the HCl salt, the

rophenol, triphenylphosphine and diisopropyl azodicarboxy
late in a solvent consisting of ether and hexanes in a 1:1 ratio

temperature over a period of four hours. This particular sol
vent combination alloWs for complete dissolution of all start

35

ing materials and initiation of the precipitation of triph
enylphosphine oxide from the reaction mixture. The

utilization of anhydrous grades of these solvents during the
preparation of 24 is not necessary, in contrast to What gener

ally is used for this type of transformation. After completion
of the reaction (about 4 hours), the precipitation of triph
enylphosphine is completed by dilution of the reaction mix
ture With heptane to tWice its volume. After ?ltration, the
?ltrate is evaporated to an amber oil (crude 24) Which is
subjected to the next step Without any further puri?cation, in

compound 26. The solvents and their ratios are tailored to

achieve this precipitation. The use of anhydrous HCl in
45

scales and generally produces a voluminous precipitate of the

Compound 2, the enantiomer of (+)-lofexidine (2) and its
hydrochloride salt may be obtained in a similar fashion, start
50

can be accomplished by treatment With ammonia. In one

embodiment, the (+) or (—) 1-methyl-1-[2,6-dichlorophe

hours to provide partial crystallization of the product 25 from

55

ethanamide is converted to (+) or (—) imino-ether intermedi
ate by electrophilic attack of the amide oxygen by a tri
methoxonium ion and, Without isolation, converting the (+) or

Although the present invention has been described in detail
With reference to the example beloW, it is understood that
various modi?cations can be made Without departing from
the spirit of the invention, and Would be readily knoWn to the
skilled artisan.

(—)-2-(2,6-dichlorophenoxy)-propionamide (25). To 1-L

?ltered to provide a clear, pale yelloW ?ltrate that yields large

Then, the (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]

ing With the (+)-methyl lactate (23).

EXAMPLE

the reaction mixture. The reaction is then re?uxed to drive off
excess ammonia and diluted With boiling ethanol to dissolve
the entirety of the solid mass. Undissolved solids are then

needles of pure 25 upon cooling to 0° C.

i-PrOH, as knoWn in the literature, is tedious to use on large

salt.

Next, the (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]

noxy]ethanoate is converted to the amide by treatment With a
solution of ammonia in an alcohol. For example, crude 24 is
treated With a solution of ammonia in absolute ethanol for 12

crystalline material (3) is dissolved in a 4:1 mixture of ether
and i-PrOH and is treated With 1.2 equiv. of aqueous conc.
HCl. This results in precipitation of very ?ne colorless
needles that are recovered by ?ltration and dried in air.
The present invention’s conversion to the HCl salt advan
tageously uses aqueous HCl rather than anhydrous HCl as
taught in the literature. The use of the 4:1 mixture of ether and
i-PrOH and With 1.2 equiv. of aqueous conc. HCl alloWs for

the precipitation of a microcrystalline hydrochloride salt of 3,

this speci?c example.
ethanoate is converted to (+) or (—) 1-methyl-1-[2,6-dichlo
rophenoxy]ethanamide. Conversion of the ether to the amide

This material is chemically and optically pure, as judged from
its NMR spectra and optical rotation values.

The resulting (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]

For example, methyl ester 22 is reacted With 2,6-dichlo
at 0° C. and the reaction mixture is alloWed to Warm to room

clear solution upon stirring for 36 hours at room temperature.

This solution, containing an imino-ether intermediate, is

dichlorophenol, triphenylphosphine and diisopropyl azodi
carboxylate and precipitates triphenylphosphine oxide. The

round bottom ?ask equipped With a stir-bar Were added (+)
60

methyl lactate (25.00 g, 240.26 mmol), Ph3P (63.00 g, 241
mmol), and 2,6-dichlorophenol (39.16 g, 240.26 mmol) and
ether-hexanes (1:1, 250 mL). After cooling to 0° C., DIAD

(—) imino-ether intermediate to (+) or (—) 2-[1-(2,6-dichlo

(49.00 g, 241 mmol) Was added dropWise over 30 minutes and
the resulting yelloW solution Was Warmed to room tempera
ture over a period of 4 hours, during Which, ?ne White needles

ene diamine. In one embodiment, the trimethoxonium ion is

of triphenyl phosphine oxide crystallized. The mixture Was
diluted With 250 mL of heptanes, stirred for 30 minutes and

rophenoxy)-ethyl]1,3-diazacyclopent-2-ene by adding ethyl

US 8,101,779 B2
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12
(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZa
cyclopent-2-ene into a pharmaceutically acceptable acid

?ltered through a Buchner funnel. The ?lter cake Was Washed

With heptane (100 mL, 2x) and the ?ltrates Were evaporated to
an amber oil containing 24, that Was directly subjected to the
next transformation Without any further puri?cation.
The amber oil obtained above (65 g crude) Was dissolved in

addition salt thereof.
2. The enantioselective synthesis of claim 1 Wherein the
trimethoxonium ion is trimethyloxonium tetra?uoroborate.
3. The enantioselective synthesis of claim 1 Wherein
approximately 1.1 equivalents ethylene diamine are added as

500 mL absolute EtOH and cooled to 0° C. Ammonia gas Was

passed through this solution until the solution Was judged to
be saturated (seen as greatly increased bubbling of gas). The

an alcohol solution.

mixture Was alloWed to Warm to room temperature (unstirred)

4. The enantioselective synthesis of claim 1 Wherein the (+)
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent
2-ene is crystalliZed from hexanes.
5. The enantioselective synthesis of claim 1 Wherein the (+)
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent
2-ene is converted into a HCl salt by dissolving and treating

over 12 h, folloWing Which, it Was re?uxed for 15 min. and
diluted With EtOH (250 mL) and re?uxed for 30 min. This
mixture Was ?ltered hot and the ?ltrate Was cooled in the
refrigerator for 2 h Which led to the formation of a mass of

White needles, that Was removed by ?ltration and dried in air

for 30 min to yield 25 (50.00 g, 89%). 1H NMR (300 MHZ,
CDCl3) 6 ppm 7.35-7.25 (m, 2H, Ar), 7.03 (t, J:8.4 HZ, 1H,
Ar), 6.93 (br, s, NH), 6.08 (br, s, NH), 4.93 (q, 1H, 1:69 HZ),
1.50 (d, 3H, 1:69 HZ); 13C NMR (75 MHZ, CDCl3) 6 ppm

With aqueous concentrated HCl.

6. The enantioselective synthesis of claim 5 Wherein the (+)
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent
2-ene is converted into a HCl salt by dissolving in an approxi

174.2, 148.9, 129.7, 129.4, 125.7, 79.3, 18.1; mp:192-193o
C. (EtOH); [0t]23D:—18.9° (c 1.0, EtOH) (lit.4 [0t]2OD:—20. 1 °

(c 1.0, acetone).
(—)-2- [1 -(2, 6-dichlorophenoxy) -ethyl] -1 ,3 -diaZacyclo

mately 4: 1 mixture of ether and isopropyl alcohol and treating
20

With aqueous concentrated HCl to precipitate a microcrystal

line hydrochloride salt of (+) or (—) 2-[1-(2,6-dichlorophe

pent-2-ene (3). A mixture of 25 (25 g, 106.8 mmol), trimethy
loxonium tetra?uoroborate (16.6 g, 110 mmol) and CH2Cl2

noxy)-ethyl] 1,3 -diaZacyclopent-2-ene.

(600 mL) Was stirred for 36 hours, during Which the coarse
suspension changed to a clear, colorless solution. Cooling of
this solution of 00 C. Was folloWed by a dropWise addition of
ethylene diamine (7.00 g, 1.1 equiv) over 10 minutes. The

synthesis provides an overall yield of (+) or (—) 2-[1-(2,6

7. The enantioselective synthesis of claim 1, Wherein the
25

50%.

resulting solution Was Warmed to room temperature, diluted

8. The enantioselective synthesis of claim 1, Wherein the

With absolute ethanol (200 mL) and then evaporated to dry

synthesis provides an overall yield of (+) or (—) 2-[1-(2,6

ness. The pasty White residue Was partitioned betWeen 5%

dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar

aqueous KZCO3 (200 mL) and CH2Cl2 (500 mL). The organic

maceutically acceptable acid addition salt thereof of at least
60%.
9. An enantioselective synthesis of (+) or (—) 2-[1-(2,6

layer Was dried (Na2SO4) and evaporated under reduced pres
sure. Recrystallization of the residue from boiling hexanes
(500 mL) afforded pure 3 as White needles that Were removed

by ?ltration and dried in air (23.52 g, 85%). 1H NMR (300
MHZ, d6-DMSO) 6 ppm 7.46-7.44 (m, 2H, Ar), 7.14 (t, J:7.8

dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar
35

(a) converting (+) or (—) 1—methyl-1—hydroxyethanoate to
(+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate
40

1.0, EtOH).
(—)-2- [1 -(2, 6-dichlorophenoxy) -ethyl] -1 ,3 -diaZacyclo
pent-2-ene hydrochloride (26). To a solution of 3 (10.00 g, 39
mmol) in 4:1 ether/i-PrOH (100 mL) Was added dropWise
conc. aqueous HCl (3.5 mL, 1.1 equiv.). Upon stirring for 10
minutes the suspension Was diluted With ether (100 mL),
?ltered and the ?lter-cake Was Washed With ether (3><50 mL)

and air-dried, affording 26 (11.40 g, 100%). 1H NMR (300
MHZ, d6-DMSO) 6 ppm 10.86 (s, 2H, NH), 7.52 (d, J:8.1 HZ,
2H, Ar), 7.23 (t, J:8.1 HZ, 1H, Ar), 5.20 (q, 1:66 HZ, 1H)
3.87 (s, br, 4H), 1.66 (d, 1:66 HZ, 3H); 13C NMR (75 MHZ,
d6-DMSO) 6 ppm 169.5, 149.2, 130.3, 129.1, 127.5, 73.9,

by reacting With 2,6-dichlorophenol, triphenylphos
phine and diisopropyl aZodicarboxylate;
(b) converting the (+) or (—) 1-methyl-1-[2,6-dichlorophe
noxy]ethanoate to (+) or (—) 1-methyl-1-[2,6-dichlo

rophenoxy]ethanamide;
(c) converting (+) or (—) 1-methyl-1-[2,6-dichlorophe
45

noxy]ethanamide to (+) or (—) imino-ether intermediate
by electrophilic attack of the amide oxygen by a tri
methoxonium ion and Without isolation converting the
(+) or (—) imino-ether intermediate to (+) or (—) 2-[1-(2,

6-dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2-ene by
50

adding ethylene diamine; and
(d) optionally converting the (+) or (—) 2-[1-(2,6-dichlo
rophenoxy)-ethyl] 1 ,3 -diaZacyclopent-2-ene into a phar
maceutically acceptable acid addition salt thereof.

45.2, 19.5; mp:226-227o C.; [0t]23D:—39.0° (c 1.0, EtOH)
(lit.5 [0t]2OD —34.5° (c 1.0, EtOH).

10. The enantioselective synthesis of claim 9 Wherein step
(a) is performed in a solvent that dissolves the (+) or (—)

All references cited above are incorporated herein in their

entirety for all purposes.

maceutically acceptable acid addition salt thereof compris
ing:

HZ, 1H, Ar), 6.45 (s, 1H, NH), 4.79 (q, 1:66 HZ, 1H), 3.43
3.37 (s, br, 4H), 1.47 (d, 1:66 HZ, 3H). 13C NMR (75 MHZ,
d6-DMSO) 6 ppm 166.3, 150.0, 130.0, 129.6, 129.5, 129.2,
126.6, 77.3, 50.4 (very broad), 19.2; mp:129-130o C. (hex

anes); [0t]23D:—80.2° (c 1.0, EtOH) (lit.4 [(X]2OD:—76.4o (c

dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar

maceutically acceptable acid addition salt thereof of at least

55

That Which is claimed:

1—methyl-1—hydroxyethanoate, 2,6-dichlorophenol, triph
enylphosphine and diisopropyl aZodicarboxylate and precipi

converting (+) or (—) 1—methyl-1-[2,6-dichlorophenoxy]

tates triphenylphosphine oxide.
11. The enantioselective synthesis of claim 9 Wherein step
(a) is performed in a solvent consisting of an approximately
1:1 ratio of a polor aprotic solvent and a nonpolar solvent.
12. The enantioselective synthesis of claim 9 Wherein step
(a) is performed in a solvent consisting of an approximately

ethanamide to an (+) or (—) imino-ether intermediate by
electrophilic attack of the amide oxygen by a tri

1:1 ratio of ether and hexanes.
13. The enantioselective synthesis of claim 9 Wherein in

1. An enantioselective synthesis of (+) or (—) 2-[1-(2,6
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar

maceutically acceptable acid addition salt thereof compris
60

1ng:

methoxonium ion and, Without isolation, converting the
(+) or (—) imino-ether intermediate to (+) or (—) 2-[1-(2,

6-dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2-ene by
adding ethylene diamine; and optionally converting the

step (a) the (+) or (—) 1-methyl-1—hydroxyethanoate is reacted
65

With 2, 6-dichlorophenol, triphenylphosphine and diisopropyl
aZodicarboxylate at approximately 00 C. and alloWed to Warm
to approximately room temperature.

US 8,101,779 B2
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14. The enantioselective synthesis of claim 9 wherein the

(+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate is
converted to (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]

pent-2-ene is converted into a HCl salt by dissolving in an
approximately 4: 1 mixture of ether and isopropyl alcohol and
treating With aqueous concentrated HCl to precipitate a

ethanamide by treatment of a solution of ammonia in an

microcrystalline hydrochloride salt of (+) or (—) 2-[1-(2,6

alcohol.
15. The enantioselective synthesis of claim 9 Wherein the

dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2 -ene.
20. The enantioselective synthesis of claim 9, Wherein the
synthesis provides an overall yield of (+) or (—) 2-[1-(2,6

trimethoxonium ion is trimethyloxonium tetra?uoroborate.
16. The enantioselective synthesis of claim 9 Wherein in

dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar

step (c) approximately 1.1 equivalents ethylene diamine are

maceutically acceptable acid addition salt thereof of at least

added as an alcohol solution.

50%.

17. The enantioselective synthesis of claim 9 Wherein the

21. The enantioselective synthesis of claim 9, Wherein the

(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo
pent-2-ene is crystallized from hexanes.

synthesis provides an overall yield of (+) or (—) 2-[1-(2,6
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar

18. The enantioselective synthesis of claim 9 Wherein the

maceutically acceptable acid addition salt thereof of at least

(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo
pent-2-ene is converted into a HCl salt by dissolving and
treating With aqueous concentrated HCl.
19. The enantioselective synthesis of claim 18 Wherein the

(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo

60%.
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